Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 48

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 48
---
11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.

In addition, a Selling Shareholder
that is an entity may elect to make a pro rata in-kind distribution of securities to its members, partners or stockholders pursuant to
the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners
or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement.

To the extent required, the
ordinary shares to be sold, the name of the Selling Shareholders, the respective purchase prices and public offering prices, the names
of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in
an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this
prospectus.

In order to comply with the
securities laws of some states, if applicable, the ordinary shares may be sold in these jurisdictions only through registered or licensed
brokers or dealers. In addition, in some states the ordinary shares may not be sold unless they have been registered or qualified for
sale or an exemption from registration or qualification requirements is available and is complied with.

We have advised the Selling
Shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of ordinary shares in the market
and to the activities of the Selling Shareholders and their affiliates. In addition, to the extent applicable we will make copies of this
prospectus (as it may be supplemented or amended from time to time) available to the Selling Shareholders for the purpose of satisfying
the prospectus delivery requirements of the Securities Act. The Selling Shareholders may indemnify any broker-dealer that participates
in transactions involving the sale of the ordinary shares against certain liabilities, including liabilities arising under the Securities
Act.

We will bear all costs, expenses
and fees associated with the registration of the securities covered by this prospectus.

In compliance with the guidelines of the Financial
Industry Regulatory Authority (“FINRA”), the aggregate maximum discount, commission, fees or other items constituting underwriting
compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the gross proceeds of any offering
pursuant to this prospectus and any applicable prospectus supplement.

<div align='center'>24

EXPENSES OF THE OFFERING</div>

The